{"success":true,"data":{"pressRelease":{"id":"38101","rtpr_id":"nWkr2xCQZV","ticker":"EMBLA","exchange":"Nasdaq Copenhagen","all_tickers":["EMBLA"],"title":"Embla Medical hf: Transactions in relation to Share Buyback Program","author":"Cision","published_at":"2026-05-18T15:00:12.925Z","article_body":"Embla Medical hf.\nAnnouncement no. 27/2026\n\n18 May 2026\n\nReykjavik, Iceland/Copenhagen, Denmark, 18 May 2026. Embla Medical (Nasdaq\nCopenhagen: EMBLA), a leading global provider of innovative mobility\nsolutions, today announced transactions in relation to its share buyback\nprogram (“Program”), see also Company Announcement no. 61/2025 dated 23\nDecember 2025.\n\nDuring the period 11 May to 13 May 2026 Embla Medical has acquired 101,000\nshares under the Program at the average price of DKK 26.75. Following the\ntransactions below, the Company holds 1,492,457 shares, corresponding to 0.35%\nof the Company’s total share capital.\n\n Transaction date    No. of shares  Avg. purchase price in DKK  Transaction value in DKK  \n 11 May 2026         6,000          27.27                       163,600                   \n 12 May 2026         65,000         26.90                       1,748,819                 \n 13 May 2026         30,000         26.30                       788,999                   \n Total               101,000        26.75                       2,701,418                 \n\nThe purpose of the Program is to reduce the Company’s share capital and\nadjust the capital structure by distributing capital to shareholders in line\nwith the Company’s Capital Structure and Capital Allocation Policy. The\nProgram will end no later than 31 December 2026, but the Company is entitled\nto discontinue the Program at any time.  \n\nThe Company may purchase up to 2,000,000 shares under the Program,\ncorresponding to 0.46% of the current share capital. The total consideration\nfor shares purchased under the Program shall not exceed USD 10 million.\n\nThe Program on Nasdaq Copenhagen is carried out in accordance with Regulation\nNo. 596/2014 of the European Parliament and of the Council on market abuse\n(\"MAR\"), and the Commission’s delegated regulation 2016/1052.\n\nFurther information\n\nKlaus Sindahl, Head of Investor Relations, KSindahl@emblamedical.com, +45 5363\n0134\n\nEmbla Medical press releases by e-mail\n\nIf you wish to receive Embla Medical press releases by e-mail, please register\nat http://www.emblamedical.com/investors\n\nAbout Embla Medical\n\nEmbla Medical (Nasdaq Copenhagen: EMBLA) is a leading global provider of\ninnovative mobility solutions that help people live a Life Without\nLimitations(®). Embla Medical is home to several leading brands renowned for\npositively impacting people's health and well-being. They include Össur, a\nleading global provider of prosthetics and bracing solutions; Fior & Gentz, an\ninnovative developer of neuro orthotics; College Park, a provider of lower\nlimb prosthetics; and ForMotion, a global network of Orthotic and Prosthetic\n(O&P) patient care facilities. Embla Medical is committed to sustainable\nbusiness practices, is a signatory to the UN Global Compact and UN Women’s\nEmpowerment Principles and contributes to the UN Sustainable Development\nGoals. The company's climate targets have been verified by the Science Based\nTargets initiative. Embla Medical operates globally and has around 4,500\nemployees. www.emblamedical.com\n\nhttps://news.cision.com/embla-medical-hf-/r/embla-medical-hf--transactions-in-relation-to-share-buyback-program%2Cc4349426\n\n20260518 Embla Announcement 27 Share Repurchase Specification\n(https://mb.cision.com/Main/18404/4349426/4095260.pdf)\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr2xCQZV","title":"Embla Medical hf: Transactions in relation to Share Buyback Program","author":"Cision","ticker":"EMBLA","created":"2026-05-18T15:00:12.925Z","tickers":["EMBLA"],"exchange":"Nasdaq Copenhagen","article_body":"Embla Medical hf.\nAnnouncement no. 27/2026\n\n18 May 2026\n\nReykjavik, Iceland/Copenhagen, Denmark, 18 May 2026. Embla Medical (Nasdaq\nCopenhagen: EMBLA), a leading global provider of innovative mobility\nsolutions, today announced transactions in relation to its share buyback\nprogram (“Program”), see also Company Announcement no. 61/2025 dated 23\nDecember 2025.\n\nDuring the period 11 May to 13 May 2026 Embla Medical has acquired 101,000\nshares under the Program at the average price of DKK 26.75. Following the\ntransactions below, the Company holds 1,492,457 shares, corresponding to 0.35%\nof the Company’s total share capital.\n\n Transaction date    No. of shares  Avg. purchase price in DKK  Transaction value in DKK  \n 11 May 2026         6,000          27.27                       163,600                   \n 12 May 2026         65,000         26.90                       1,748,819                 \n 13 May 2026         30,000         26.30                       788,999                   \n Total               101,000        26.75                       2,701,418                 \n\nThe purpose of the Program is to reduce the Company’s share capital and\nadjust the capital structure by distributing capital to shareholders in line\nwith the Company’s Capital Structure and Capital Allocation Policy. The\nProgram will end no later than 31 December 2026, but the Company is entitled\nto discontinue the Program at any time.  \n\nThe Company may purchase up to 2,000,000 shares under the Program,\ncorresponding to 0.46% of the current share capital. The total consideration\nfor shares purchased under the Program shall not exceed USD 10 million.\n\nThe Program on Nasdaq Copenhagen is carried out in accordance with Regulation\nNo. 596/2014 of the European Parliament and of the Council on market abuse\n(\"MAR\"), and the Commission’s delegated regulation 2016/1052.\n\nFurther information\n\nKlaus Sindahl, Head of Investor Relations, KSindahl@emblamedical.com, +45 5363\n0134\n\nEmbla Medical press releases by e-mail\n\nIf you wish to receive Embla Medical press releases by e-mail, please register\nat http://www.emblamedical.com/investors\n\nAbout Embla Medical\n\nEmbla Medical (Nasdaq Copenhagen: EMBLA) is a leading global provider of\ninnovative mobility solutions that help people live a Life Without\nLimitations(®). Embla Medical is home to several leading brands renowned for\npositively impacting people's health and well-being. They include Össur, a\nleading global provider of prosthetics and bracing solutions; Fior & Gentz, an\ninnovative developer of neuro orthotics; College Park, a provider of lower\nlimb prosthetics; and ForMotion, a global network of Orthotic and Prosthetic\n(O&P) patient care facilities. Embla Medical is committed to sustainable\nbusiness practices, is a signatory to the UN Global Compact and UN Women’s\nEmpowerment Principles and contributes to the UN Sustainable Development\nGoals. The company's climate targets have been verified by the Science Based\nTargets initiative. Embla Medical operates globally and has around 4,500\nemployees. www.emblamedical.com\n\nhttps://news.cision.com/embla-medical-hf-/r/embla-medical-hf--transactions-in-relation-to-share-buyback-program%2Cc4349426\n\n20260518 Embla Announcement 27 Share Repurchase Specification\n(https://mb.cision.com/Main/18404/4349426/4095260.pdf)\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026"},"type":"article","timestamp":"2026-05-18T15:00:12.996763385Z","server_sent_at_ms":1779116412996},"received_at":"2026-05-18T15:00:13.056Z","source_url":"https://news.cision.com/embla-medical-hf-/r/embla-medical-hf--transactions-in-relation-to-share-buyback-program%2Cc4349426"},"analysis":{"id":"27542","press_release_id":"38101","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":[],"eventType":"buyback","narrative":"Embla Medical repurchased 101,000 shares between May 11 and May 13, 2026, at an average price of DKK 26.75.\n\nThe transactions totaled DKK 2.7 million, bringing the company’s total treasury shares to 1,492,457, or 0.35% of total share capital.\n\nThe buyback program, authorized in December 2025, allows for the purchase of up to 2 million shares (0.46% of capital) for a maximum of USD 10 million and runs until December 31, 2026.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine buyback execution; low signal for downstream posting."},"keyFigures":{"offeringPrice":26.75,"sharesOffered":101000,"customDimensions":{"program_max_shares":2000000,"program_max_value_usd":10000000,"percentage_of_share_capital":"0.35%","total_transaction_value_dkk":2701418,"shares_held_post_transaction":1492457}},"quotedText":"The purpose of the Program is to reduce the Company’s share capital and adjust the capital structure by distributing capital to shareholders in line with the Company’s Capital Structure and Capital Allocation Policy.","namedEntities":{"people":[{"name":"Klaus Sindahl","role":"Head of Investor Relations"}],"products":[],"companies":[{"name":"Embla Medical hf.","ticker":"EMBLA","relationship":"filer"},{"name":"Össur","relationship":"subsidiary/brand"},{"name":"Fior & Gentz","relationship":"subsidiary/brand"},{"name":"College Park","relationship":"subsidiary/brand"},{"name":"ForMotion","relationship":"subsidiary/brand"}],"dollarAmounts":[{"amount":"USD 10 million","context":"maximum total consideration for the buyback program"},{"amount":"DKK 2,701,418","context":"total transaction value for the reported period"}]},"materialImpact":{"score":2,"reasoning":"Routine execution of an authorized share buyback program. The volume (101k shares, ~0.35% of capital) and value (~$400k USD) are immaterial relative to the company's total capitalization and the $10M program cap. No new authorization or strategic shift is announced."},"tickerRelevance":{"others":[],"primary":"EMBLA"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_buyback_execution","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"buyback","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Embla Medical repurchased 101,000 shares between May 11 and May 13, 2026, at an average price of DKK 26.75.\n\nThe transactions totaled DKK 2.7 million, bringing the company’s total treasury shares to 1,492,457, or 0.35% of total share capital.\n\nThe buyback program, authorized in December 2025, allows for the purchase of up to 2 million shares (0.46% of capital) for a maximum of USD 10 million and runs until December 31, 2026.","key_figures":{"offeringPrice":26.75,"sharesOffered":101000,"customDimensions":{"program_max_shares":2000000,"program_max_value_usd":10000000,"percentage_of_share_capital":"0.35%","total_transaction_value_dkk":2701418,"shares_held_post_transaction":1492457}},"named_entities":{"people":[{"name":"Klaus Sindahl","role":"Head of Investor Relations"}],"products":[],"companies":[{"name":"Embla Medical hf.","ticker":"EMBLA","relationship":"filer"},{"name":"Össur","relationship":"subsidiary/brand"},{"name":"Fior & Gentz","relationship":"subsidiary/brand"},{"name":"College Park","relationship":"subsidiary/brand"},{"name":"ForMotion","relationship":"subsidiary/brand"}],"dollarAmounts":[{"amount":"USD 10 million","context":"maximum total consideration for the buyback program"},{"amount":"DKK 2,701,418","context":"total transaction value for the reported period"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-18T15:02:57.546Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_buyback_execution","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":25334,"modelName":"george-droid-qwen-72b"}}